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 Methylation of DNA cytosine bases is an essential and well-studied epigenetic 
modification that may regulate and coordinate gene expression. Methylated 
gene promoter or enhancer regions are thought to block accessibility to 
transcriptional activators and prevent gene transcription. Numerous 
physiological and disease states have been associated with alterations in 
DNA methylation, with patterns shown to change over time in distinct cell 
types.1 The majority of this plasticity is explained by DNA variants, likely to be 
working through a downstream effect of sequence variation on transcription 
factor activity.2,3 However, more controversially, environmental exposures, 
including events such as famine, may affect DNA methylation patterns,4,5 
which in addition, can be propagated to daughter cells during cell division6 
and influence the transcription of associated genes through diverse and as yet 
poorly understood mechanisms.3 The potential link between environment, 
changes in DNA methylation and resultant variation in gene expression that 
may translate into particular cellular phenotypes, has made this topic 
attractive to many researchers in biomedicine.  
 
Study of DNA methylation in disease may be able to define regions of DNA 
that are differentially methylated between cases and controls. Knowledge of 
these differences could aid understanding of the pathogenesis of the disease 
under study or allow characterization of novel biomarkers. Importantly, DNA 
methylation may go some way to explain the significant non-genetic 
contributions to autoimmune diseases, which have proven to be elusive to 
date.  So far, use of diverse high throughput technologies has provided 
mechanistic information on how abnormal methylation patterns correlate with 
disordered gene expression.7 Furthermore, biomarkers based on the 
methylation status of small sets of genes have been validated as predictors of 
different outcomes in some cancers.8 
  
In this issue of the Journal of the American Society of Nephrology, Jones et 
al.9 present a study of DNA methylation in patients with Anti-neutrophil 
cytoplasm antibody (ANCA) associated vasculitis (AAV) using whole blood 
analysis. AAV is a relapsing and remitting autoimmune disease, generally 
characterised by circulating ANCA, reactive to proteinase 3 (PR3) or 
myeloperoxidase (MPO) and thought to be triggered by certain environmental 
exposures, such as silica dust, infections, or drug exposure. Different disease 
phenotypes are recognised and more recently different genetic susceptibility 
loci have been identified according to ANCA serotype, with polymorphisms in 
HLA, PRTN3 and SERPINA1, encoding MHC molecules, PR3 and its natural 
inhibitor alpha-1-antitrypsin respectively, being associated with PR3-ANCA 
disease.10 In their study, Jones et al, firstly examined methylation and gene 
expression in AAV patients and healthy controls. Secondly, they investigated 
whether DNA methylation patterns can be used to predict disease relapse.  
 
In the first part, Jones et al. selected two regions of the genes, MPO and 
PRTN3, which encode the autoantigens MPO and PR3 respectively, and 
interrogated the DNA methylation status of these two regions. They found that 
in both genes DNA methylation was reduced in active disease compared to 
healthy controls, and rebounded in disease remission. They then examined 
expression of MPO and PRTN3 and found a negative correlation between 
DNA methylation and gene expression, with higher methylation levels of the 
assayed gene sites being associated with less expression of associated 
genes.  
 
They then narrowed their study to paired samples from a subset of patients 
assessed longitudinally, during active disease and remission. This 
investigation showed that, although statistically DNA methylation was more 
likely to increase at the MPO and PRTN3 loci upon remission, patients could 
be stratified into groups who increased or decreased methylation at these loci. 
Integrating expression and methylation data suggested that patients showing 
gene specific DNA methylation increases during remission showed a 
correlation with reduced expression of the associated autoantigen gene. 
 
The second part of the study sought to establish if DNA methylation might 
associate with disease relapse. Patients who increased DNA methylation at 
the PRTN3 locus during remission were less likely to relapse regardless of 
their autoantigen serotype. Additionally, in univariate and multivariate 
analyses, PRTN3 methylation status remained strongly associated with 
relapse, as patients with decreased PRTN3 promoter methylation were 
significantly more likely to relapse than other patients. 
 
This study has a number of strengths. It suggests that AAV patients have 
distinct epigenetic phenotypes and that these differences in DNA methylation 
can be associated with both a cellular phenotype - that of differing autoantigen 
gene expression, and a key clinical consideration - disease relapse. The 
correlation between methylation and gene expression may in the future be 
able to shed light on the mechanism underlying ANCA formation and may 
elicit novel therapeutic targets. The possible association of DNA methylation 
and relapse may lead to a useful biomarker that could guide cessation or 
intensification of therapy. 
 
However, there are points for consideration when building on this study in the 
future. As interest in methylation has grown, so has understanding of some of 
the challenges to interpreting human methylation data (Reviewed in 3,11),many 
of which are relevant to the study of Jones et al.  
 
For example, DNA methylation is largely bimodal, with individual loci either 
fully methylated or not methylated at all. Therefore, observed methylation 
differences of approximately 10-20% may reflect varying DNA methylation 
signatures from varying proportions of different cell types making up the 
patient leukocyte samples.11 In their study, the authors could not exclude an 
impact of differential cell composition in the samples, as values for total white 
cell and neutrophil counts were missing in a significant proportion of the 
samples. Future studies could address this by using purified samples of a 
single cell subtype, or utilizing the emerging technique of single cell 
methylation analysis.12 However, a further challenge is then that an overall 
10-20% methylation difference may be illustrative of a mosaic subset of cells 
with distinct methylation states.11 
 
Another important consideration for the design of future experiments is DNA 
sequence variation. The clear importance of genetic influence on DNA 
methylation patterns has recently been demonstrated, and the complex and 
context specific interaction of sequence, methylation, transcription factor 
activity and gene expression remains an area of intense study.13 As a result, 
drawing conclusions on the role of DNA methylation patterns in disease 
pathogenesis would be greatly enhanced by datasets assaying all of this 
information simultaneously. 
 
Independent of using DNA methylation experiments to gain insight into 
mechanisms of disease, reproducible epigenetic signatures could be useful as 
biomarkers or prognostic indicators in the disease course. Again, in order to 
remove the confounder of sample cell compositions, assaying purified cell 
populations may be critical for the development of this field. Additionally, DNA 
methylation must be considered as a phenotype (such as proteinuria) that can 
change over time.11 Therefore, future experiments will need to prospectively 
evaluate the predictive ability of biomarkers based on epigenetic modifications 
over a longer follow-up period. Once the dynamic changes in methylation 
phenotype which occur over the course of disease are better understood, this 
will raise the issue of what time points to compare to provide the most robust 
prediction for future outcomes such as relapse. In addition, it is important to 
consider the impact of therapy on methylation status. Although the authors 
have attempted to address this by considering the impact of glucocorticoid 
use, the effect of cytotoxic or other depletional agents was not taken into 
account.  Previous studies have suggested that IL-6 blockade for example 
can impact on methylation status in SLE patients.  
 
The study results raise some other interesting questions regarding the 
fundamental biology of AAV.  Why does regulation of the PR3 locus predict 
relapses in patients with MPO-ANCA? Does modulation of PR3 in turn 
regulate MPO expression? Intriguingly, why doesn’t MPO methylation predict 
changes in MPO expression? Is this related to other epigenetic modifications 
such as the histone modifications of the MPO promoter which was associated 
with reduced MPO transcription?14 Additionally, if PR3 gene expression 
predicts relapse and influences MPO expression, how to explain the genome 
wide association study data demonstrating differential gene influence based 
on ANCA serotype10 and the lower relapse rates found in MPO-ANCA 
patients compared to those with PR3-ANCA? Finally, what environmental 
factors are altering methylation status and can these be targeted and 
modified? 
 
An important aspect to consider is the need for a validation cohort to ensure 
that the findings from the studied cohort can be generalised to other AAV 
populations. Clearly, the study patients were carefully selected, and although 
enriched for previous relapse, there appeared to be no episodes of relapse in 
patients in the longitudinal arm between the active and remission study time 
points, and unusually  the ANCA serotype had no impact on frequency of 
disease relapse.  These issues and questions can be tackled by performing 
future prospective studies. 
 
Overall, the work of Jones et al. represents a first and significant step linking 
epigenetic modifications and disease phenotype in AAV. There are other 
epigenetic mechanisms to be considered including the role of non-coding 
RNAs and histone modifications which could be addressed together in the 
future. There has been a recent explosion of epigenetic studies guided by 
large consortia and using sophisticated whole genome analyses15. Much of 
this work has looked specifically at immune phenotypes and leukocyte 
subtypes, which are key players in mediating autoimmune disease in 
response to environmental cues. Therefore, the study by Jones should 
represent a springboard from which the nephrology and vasculitis 
communities embrace these novel approaches and further investigate the role 
of epigenetic modifications in immune mediated kidney diseases. 
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